Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial

医学 美洛昔康 安慰剂 强直性脊柱炎 吡罗昔康 内科学 随机对照试验 药品 麻醉 药理学 病理 替代医学
作者
Maxime Dougados
出处
期刊:British journal of rheumatology 卷期号:38 (3): 235-244 被引量:158
标识
DOI:10.1093/rheumatology/38.3.235
摘要

OBJECTIVE: To consider the relevance of the duration of a clinical trial in ankylosing spondylitis: long-term (i.e. 1 yr) vs short-term (i.e. 6 weeks) assessment of a non-steroidal anti-inflammatory drug (NSAID)-placebo controlled study. METHODS: The design was a prospective, multicentre, double-blind, placebo-controlled study of 6 weeks duration with a 12 months double-blind extension. Study drugs were placebo (n = 121) or active NSAID (n = 352). A decrease of at least 50% in pain and/or global assessment and/or functional impairment during the study defined the response to treatment. The percentage of patients discontinuing the study drug over time (life table analysis) permitted the evaluation of both the efficacy and toxicity. RESULTS: Among the 473 recruited patients, the percentage of responders was similar at 1 yr and week 6 with a highly statistically significant difference in favour of the active NSAID groups when compared to placebo (at 1 yr, 17% in the placebo group vs 37, 50 and 43% in the piroxicam 20 mg, meloxicam 15 mg and meloxicam 22.5 mg, respectively, for the patient's overall assessment) without any statistically significant difference between the three active groups. However, evaluation of the patients discontinuing the study drug during the 1 yr of the study permitted the detection of a statistically significant difference between the active NSAID groups. A lower percentage of patients taking meloxicam 22.5 mg had to discontinue the study drug when compared to either meloxicam 15 mg or piroxicam 20 mg (37% vs 53% and 53%, respectively, P < 0.05). By 52 weeks, drug-related upper gastrointestinal adverse events occurred in 13, 32, 20 and 18% in the placebo, piroxicam 20 mg, meloxicam 15 mg and meloxicam 22.5 mg groups, respectively. Some of the adverse events occurred only after week 6. CONCLUSION: This study suggests that a 1 yr trial might be of optimum value compared to a 6 week assessment in order to define better the efficacy and tolerability of NSAIDs in ankylosing spondylitis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Vicky完成签到,获得积分10
刚刚
谷得猫宁完成签到,获得积分20
刚刚
orixero应助儒雅致远采纳,获得10
3秒前
Vicky发布了新的文献求助10
3秒前
1351567822应助传统的迎南采纳,获得10
4秒前
充电宝应助一颗椰子糖耶采纳,获得10
4秒前
丘比特应助ultramix采纳,获得10
5秒前
5秒前
Rondab应助糊涂的雪珊采纳,获得30
6秒前
潜水读者完成签到,获得积分10
7秒前
diu完成签到,获得积分20
7秒前
10秒前
11秒前
11秒前
12秒前
MQL完成签到,获得积分10
12秒前
小垃圾发布了新的文献求助10
12秒前
13秒前
莫遥完成签到 ,获得积分10
13秒前
zkwgly完成签到,获得积分10
13秒前
鱼蛋关注了科研通微信公众号
15秒前
15秒前
Ran发布了新的文献求助10
16秒前
如意枫叶发布了新的文献求助10
16秒前
zkwgly发布了新的文献求助10
16秒前
张雯思发布了新的文献求助10
16秒前
小蛮样完成签到,获得积分10
17秒前
tg2024完成签到,获得积分10
17秒前
18秒前
18秒前
dicc发布了新的文献求助10
18秒前
玄月发布了新的文献求助10
18秒前
冯冯完成签到,获得积分10
18秒前
19秒前
20秒前
23秒前
23秒前
sxhdxwf发布了新的文献求助30
24秒前
24秒前
勤奋的从梦完成签到,获得积分10
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989711
求助须知:如何正确求助?哪些是违规求助? 3531864
关于积分的说明 11255235
捐赠科研通 3270505
什么是DOI,文献DOI怎么找? 1804983
邀请新用户注册赠送积分活动 882157
科研通“疑难数据库(出版商)”最低求助积分说明 809176